EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Outcomes of daratumumab–bortezomib–thalidomide–dexamethasone in treatment‐naive systemic AL amyloidosis

Jahanzaib Khwaja iD, Sriram Ravichandran iD, Oliver Cohen, Darren Foard, May Low, Ana Martinez-Naharro, Lucia Venneri, Marianna Fontana, Philip N Hawkins, Julian Gillmore, Helen J Lachmann, Carol Whelan und 2 weitere

British Journal of Haematology · 2025

DOI: 10.1111/bjh.20021 ↗

Kurz gefasst

Fachartikel in der Zeitschrift British Journal of Haematology, 2025. Verfasst von Jahanzaib Khwaja und 13 weiteren Autor:innen. Beteiligte Einrichtung: University College London Hospital, London, UK. Hauptthemen laut MEDLINE: Immunoglobulin Light-chain Amyloidosis, Antineoplastic Combined Chemotherapy Protocols. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 32 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Systemic light chain (AL) amyloidosis is an incurable disorder caused by extra‐cellular deposition of light‐chain aggregates in critical organs. An immunomodulatory agent‐based quadruplet including anti‐CD38 therapy has not been investigated as a first‐line treatment in AL amyloidosis. We report the UK experience of daratumumab–bortezomib–thalidomide–dexamethasone for the first‐line treatment of AL amyloidosis. Consecutive patients with a new diagnosis of systemic AL between 2021 and 2023 were retrospectively reviewed from the UK National Amyloidosis Centre database. One hundred and two patients were included; median age was 61 years, involved free light‐chain concentration 234 mg/L, 65% had cardiac and 63% renal involvement with modified Mayo stage I/II/IIIa/IIIb in 24%/36%/21% and 19% respectively. A median of 6 cycles was delivered. By intention‐to‐treat analysis, best haematological overall response rate was 97%: complete response at 65%, very good partial response at 22%, partial response at 11% and no response at 3%. At 6‐ and 12‐month time points from treatment initiation, best cardiac response rates were 39% and 45%, respectively, for evaluable patients. At a median duration of 18 months follow‐up, the estimated 1‐year overall survival was 89% (95% confidence interval [CI] 81–94) and treatment‐free survival/death was 82% (95% CI 73–89). We demonstrate efficacy in this real‐world population with comparable results to the gold standard, daratumumab–bortezomib–cyclophosphamide–dexamethasone.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Immunoglobulin Light-chain AmyloidosisAntineoplastic Combined Chemotherapy ProtocolsHumansDexamethasoneBortezomibMiddle AgedMaleFemaleAgedAntibodies, MonoclonalRetrospective StudiesThalidomideAdultTreatment OutcomeAged, 80 and over

Stichwörter der Autor:innen

amyloidosischemotherapyimmunotherapy

Substanzen

daratumumabDexamethasoneBortezomibAntibodies, MonoclonalThalidomide

Autor:innen und Institutionen

  • University College London Hospital, London, UK.
  • National Amyloidosis Centre, Royal Free London Hospital, London, UK.

ORCID-Profile: Jahanzaib Khwaja, Sriram Ravichandran

Zitieren

APA

Khwaja, J., Ravichandran, S., Cohen, O., Foard, D., Low, M., Martinez-Naharro, A., Venneri, L., Fontana, M., Hawkins, P. N., Gillmore, J., Lachmann, H. J., Whelan, C., Mahmood, S., & Wechalekar, A. (2025). Outcomes of daratumumab–bortezomib–thalidomide–dexamethasone in treatment‐naive systemic AL amyloidosis. British Journal of Haematology. https://doi.org/10.1111/bjh.20021

Vancouver

Khwaja J, Ravichandran S, Cohen O, Foard D, Low M, Martinez-Naharro A, et al. Outcomes of daratumumab–bortezomib–thalidomide–dexamethasone in treatment‐naive systemic AL amyloidosis. British Journal of Haematology. 2025. doi:10.1111/bjh.20021

BibTeX
@article{Khwaja2025,
  author = {Khwaja, Jahanzaib and Ravichandran, Sriram and Cohen, Oliver and Foard, Darren and Low, May and Martinez-Naharro, Ana and Venneri, Lucia and Fontana, Marianna and Hawkins, Philip N and Gillmore, Julian and Lachmann, Helen J and Whelan, Carol and Mahmood, Shameem and Wechalekar, Ashutosh},
  title = {Outcomes of daratumumab–bortezomib–thalidomide–dexamethasone in treatment‐naive systemic AL amyloidosis},
  journal = {British Journal of Haematology},
  year = {2025},
  doi = {10.1111/bjh.20021}
}
Kostenlos starten →